KI & Roche Oncology Workshop
The KI and Roche Oncology workshop introduces the ambitions and ongoing efforts under the Master Collaboration Agreement (MCA), active since Dec. 2014.
Oncology workshop info
Welcome to the KI-Roche Oncology Workshop to network and to learn about the Master Collaboration Agreement and possibilities for joint projects.
Time: October 19-20, 2015.
Place: Nobel Forum
12:00 - 12:30 Workshop opening, networking & sandwich lunch for all
12:30 - 12:40 Klas Wiman, KI
Introduction and welcome - why are we here today
12:40 - 13:10 Pablo Umana, Roche
Key note: Introduction - who is Roche
13:10 - 13:40 Sten Eirik W. Jacobsen, KI & University of Oxford, UK
Key note: “Getting at the roots of Cancer: Identification, surveillance and targeting of cancer stem cells”
13:40 - 14:00 Arne Östman, KI & Christian Klein, Roche
"FAP - a candidate tumor stroma drug target"
14:00 - 14.15 Coffee
14.15 - 16.00 WS 1 & 2, pre-pregistration required
WS 1: Immunotherapy (Co-Chairs: Andreas Lundqvist, KI & Volker Teichgraeber, Roche)
WS 2: Tumor microenvironment (Co-Chairs: Arne Östman, KI & Fabien Gaire, Roche)
16.00 - 16.20 Coffee break and return to lecture hall
16.20 - 17.00 Panel discussion: Highlights WS1 & WS2 - potential projects
Workshop leads, Chair: Pavel Pisa
08.30 - 09.15 Garret Hampton, Genentech
Key note: NGS/Genetics/ FMI
09.15 - 11.00 WS 3 & 4, pre-registration required
WS 3: Biomarkers, discovery and development (Co-Chairs: Jonas Bergh, KI & Astrid Kiermaier, Roche)
WS 4: Genetics/ NGS (Co-Chairs: Henrik Grönberg, KI & Jim Bischoff, Roche)
11.00 - 11.20 Coffee
11.20 - 12.00 Panel discussion: Highlights WS3 & WS4 - potential projects
Workshop leads, Chair: TBA
12.00 - 12.30 Hans-Gustaf Ljunggren (KI) & Gerd Maass (Roche)
End note – value statement of strategic partnership
The Master Collaborative Agreement (MCA) for strategic collaboration in the Cancer Research field was signed by KI and Roche global research organization in December 2014. The aim is to develop new and better therapies and more specific methods for analyses, but also to identify novel signal pathways that can be targets for future drugs.
Joint Steering Committee
Members: Astrid Kiermaier (Roche), Pavel Pisa (Roche), Rune Toftgård (KI) and Klas Wiman (KI). Chair: Gabriele Beer (Roche).
Alliance Directors: Björn Arvidsson (Roche) and Mats Ferm (KI).
The Joint Steering Committee meets regularly (2-4 times yearly).